GlassScriptPhysician profile
Marissa Vartak
NPI 1821537945
$4,267.11
in general payments reported to CMS, 2019-2025
26 companies · $939 in 2025
The $939 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,336 · 2023: $1,058 · 2024: $935 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,922 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.95 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,060.53 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $928.32 | 2022-2025 | |
| Lilly USA, LLC | $424.63 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $219.76 | 2024-2025 | Auvelity |
| Grifols USA, LLC | $214.53 | 2022-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $208.40 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $173.81 | 2022-2024 | Trintellix |
| Pfizer INC. | $152.05 | 2022-2025 | |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $118.20 | 2023 | Verquvo |
| Exact Sciences Corporation | $112.23 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $91.50 | 2023 | Dexcom G7 Gss (161) |
| Phathom Pharmaceuticals, INC. | $89.75 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.46 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $69.04 | 2022-2024 | Trelegy Ellipta, Arexvy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $23.00 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $22.07 | 2025 | Qelbree |
| Abbott Laboratories | $21.38 | 2024 | Freestyle Libre 2 |
| Gilead Sciences, INC. | $19.41 | 2024 | |
| Medtronic, INC. | $18.97 | 2023 | Inpen Smart Insulin Delivery System |
| Amgen INC. | $18.16 | 2025 | Repatha, Otezla |
| Fisher & Paykel Healthcare INC | $18.06 | 2022 | |
| Mylan Specialty L.P. | $17.19 | 2024 | Yupelri |
| Bardy Diagnostics, INC. | $16.30 | 2022 | |
| Mimedx Group, INC. | $16.08 | 2024 | |
| Vbi Vaccine (Delaware) INC. | $13.28 | 2023 | Prehevbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Vartak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.